Feb 10 (Reuters) – Edwards Lifesciences on Tuesday forecast 2026 profit above estimates, betting on robust demand for its artificial heart valves and other medical devices, sending its shares up 3% in after-hours trading.
Investor expectations around medical device makers have grown in recent quarters as demand for surgical procedures, especially from older adults, remains elevated.
Edwards said it expects new products to be meaningful catalysts later in 2026 to fuel growth, bolstering confidence in achieving its 8% to 10% sales growth rate forecast.
“Based on multiple catalysts and the company’s strong fourth-quarter performance, we have increased confidence in our outlook for 2026,” said CEO Bernard Zovighian.
Sales of Edwards’ lead product, transcatheter aortic valve replacement device used for minimally invasive heart surgeries, rose 12% to $1.16 billion in the quarter, compared to estimates of $1.13 billion, data compiled by LSEG.
The company expects 2026 adjusted profit to be in the range of $2.90 to $3.05 per share, compared to analysts’ average estimate of $2.89 per share.
The California-based company reported quarterly revenue of $1.57 billion, topping estimates of $1.55 billion.
On an adjusted basis, it earned a profit of 58 cents per share, lower than analysts’ estimates of 62 cents per share.
(Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)
